KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Non-Current Assets (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Other Non-Current Assets for 6 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 7.18% year-over-year to $6.0 million, compared with a TTM value of $6.0 million through Dec 2025, up 7.18%, and an annual FY2025 reading of $6.0 million, up 7.18% over the prior year.
  • Other Non-Current Assets was $6.0 million for Q4 2025 at Recursion Pharmaceuticals, up from $4.2 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $9.4 million in Q2 2025 and bottomed at $35000.0 in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $4.9 million, with a median of $5.8 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets soared 12155.88% in 2022, then tumbled 99.06% in 2023.
  • Year by year, Other Non-Current Assets stood at $8.7 million in 2021, then fell by 4.0% to $8.3 million in 2022, then dropped by 20.46% to $6.6 million in 2023, then decreased by 15.09% to $5.6 million in 2024, then increased by 7.18% to $6.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for RXRX at $6.0 million in Q4 2025, $4.2 million in Q3 2025, and $9.4 million in Q2 2025.